Aurobindo Pharma to acquire A1 Biochem Group . A1 Labs LLC
Aurobindo Pharma (AUROPHARMA) said it has agreed a deal to acquire A1 Biochem Group . The company is valued at about ₹96,479 crore.
What happened
Aurobindo Pharma (AUROPHARMA) told the exchanges on 2 October 2026 at 06:05 PM that it has agreed a deal to acquire A1 Biochem Group . A1 Labs LLC.
From the filing: "We refer to our letter s dated July 23, 2026 , September 12, 2026 and October 01, 2026, informing that A pitoria Pharma Private Limited ("Apitoria"), a wholly owned subsidiary of the Company , is acqui ring the Contract Research Services business of A1 Biochem Group ."
Company snapshot
Aurobindo Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹96,479 crore.
The stock last traded at ₹1,676.8, against a 52-week range of ₹1,066.8–₹1,740 (3.6% below the high).
Before this filing the shares had moved +1.4% over the month and +4.8% over three months. Average daily turnover over the last 20 sessions was about ₹125 crore.
Promoters held 51.88% at the end of Q1 FY27, up 0.06% points from the previous quarter; 13.75% of promoter shares were pledged. Foreign institutions owned 16.38% and domestic institutions 25.10%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 7,868 | 824.8 | 14.2 |
| Q2 FY26 | 8,286 | 848.5 | 14.61 |
| Q3 FY26 | 8,646 | 910.3 | 15.67 |
| Q4 FY26 | 8,853 | 921.3 | 15.86 |
| Q1 FY27 | 9,150 | 1,032.6 | 17.86 |
What history shows
BCEIE's records show 10 previous m&a filings from the company since May 2026.
After those filings, the stock gained 0.0% on average the next trading day and was up 2.3% on average after five days (8 filings with price data).
Across 106 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +0.9% over five days; 63% of them rose the next day.
Market-wide, 1,941 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 12 Sept 2026 | M&A | −1.2% | +2.0% |
| 1 Sept 2026 | Incorporation of a new wholly owned subsidiary by the name of… | −4.0% | −1.5% |
| 5 Aug 2026 | M&A | +2.8% | +3.1% |
| 23 Jul 2026 | M&A | +1.7% | +3.7% |
| 10 Jul 2026 | M&A | −2.4% | −3.4% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
- Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong
- Aurobindo Pharma Faces ₹4.60 Cr GST Demand
- Aurobindo Pharma launches Adquey in US; Nuvama sees $300 million peak sales - CNBC TV18
- AUROPHARMA Outlook for the Week (September 28, 2026 – October 02, 2026)
- Aurobindo Pharma Subsidiary Acrotech Launches Adquey Ointment in US
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.